KLP Kapitalforvaltning AS Buys Shares of 6,700 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

KLP Kapitalforvaltning AS acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,700 shares of the company's stock, valued at approximately $277,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Jones Financial Companies Lllp lifted its position in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares in the last quarter. R Squared Ltd acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000. AlphaQuest LLC lifted its holdings in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $189,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $215,000.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded up $0.46 during midday trading on Friday, hitting $39.58. The company had a trading volume of 512,121 shares, compared to its average volume of 523,149. The business's 50-day simple moving average is $46.43 and its 200-day simple moving average is $44.00. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -19.59 and a beta of 1.00. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million for the quarter, compared to analysts' expectations of $96.64 million. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on MIRM shares. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $58.20.

Insider Activity

In other news, SVP Jolanda Howe sold 902 shares of the company's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $43,223.84. Following the transaction, the senior vice president now owns 3,524 shares of the company's stock, valued at $168,870.08. This represents a 20.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Peter Radovich sold 3,177 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $152,241.84. Following the transaction, the chief operating officer now owns 29,588 shares of the company's stock, valued at approximately $1,417,856.96. This represents a 9.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 123,442 shares of company stock valued at $5,568,733 in the last 90 days. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.